{"entity":{"id":"nct07103018","kind":"trial","name":"A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)","aka":[],"tldr":"A phase 1 trial of KTX-2001 run by K36 Therapeutics, Inc., now recruiting.","summary":"A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) is a phase 1 interventional study registered as NCT07103018 by K36 Therapeutics, Inc., with 144 participants planned, started 2025-11-21. Conditions recorded: Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients, Metastatic Castration-resistant Prostate Cancer, mCRPC, mCRPC and mCRPC (Metastatic Castration-resistant Prostate Cancer). Interventions recorded: KTX-2001 and KTX-2001 + Darolutamide (NUBEQA®).","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07103018","url":"https://clinicaltrials.gov/study/NCT07103018"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc"],"sections":[],"technologies":[],"targets":[],"drugs":["ktx-2001"],"companies":["k36-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07103018","phase":"1","setting":"Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer","sponsor":"K36 Therapeutics, Inc.","enrolled":144,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07103018/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"drug":[{"id":"ktx-2001","kind":"drug","name":"KTX-2001","route":"/drugs/ktx-2001/"}],"company":[{"id":"k36-therapeutics","kind":"company","name":"K36 Therapeutics","route":"/companies/k36-therapeutics/"}]}}